Investigational drug · Phase 2
Enicepatide
Also called: CT-388, RO7795068, RG6640
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Overweight, Overweight or Obese.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
2
Any phase or sponsor naming "Enicepatide"
First trial start
2024
Aug 16, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Enicepatide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
- Overweight
- Overweight or Obese
- Type 2 Diabetes Mellitus (T2DM)
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Enicepatide" as an intervention, largest first.
- A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityPivotal-lookingCompleted
Carmot Therapeutics, Inc.Industry
NCT06525935 · 469 participants · Start Aug 16, 2024 · Primary completion Dec 8, 2025
Drug: Placebo; Enicepatide · For: Obesity; Overweight
Sites: Birmingham, Alabama; Homewood, Alabama; Mesa, Arizona · 34 sites in all
- A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusPivotal-lookingCompleted
Carmot Therapeutics, Inc.Industry
NCT06628362 · 447 participants · Start Nov 21, 2024 · Primary completion May 29, 2026
Drug: Placebo; Enicepatide · For: Overweight or Obese; Type 2 Diabetes Mellitus (T2DM)
Sites: Birmingham, Alabama; Guntersville, Alabama; Yuma, Arizona · 70 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Future GLP-1 receptor co-agonists and their cardiac effects.
Neumann J, Kirchefer U, Hofmann B, et al. · Naunyn Schmiedebergs Arch Pharmacol 2026
- Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity.
Chakravarthy MV, Rodriguez R, Hergarden A, et al. · Mol Metab 2026
- Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity.
Jepsen MM, Christensen MB · Expert Opin Emerg Drugs 2021
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.